多西环素暴露后预防性传播感染对肠道微生物组和抗菌素耐药组的影响
研究基于DoxyPEP随机临床试验,比较多西环素暴露后预防(DP组,n=100)与标准治疗(SOC组,n=50)的男男性行为者和跨性别女性。6个月后DP组四环素耐药基因在耐药组中的比例从46%升至51%(P=2.3×10⁻²),转录组从4%升至15%(P=4.5×10⁻⁶),但肠道微生物组多样性无差异。
要点
- DP组6个月时四环素耐药基因在宏基因组耐药组中占比从46%升至51%,宏转录组从4%升至15%。
- 多西环素暴露剂量越高,四环素耐药基因富集越明显(宏基因组ρ=0.23,宏转录组ρ=0.55)。
- DP组6个月时肠道微生物组α多样性、β多样性和总细菌量无显著变化。
核心结论
- 6个月多西环素暴露后预防与肠道耐药组中四环素耐药基因比例增加及四环素耐药基因表达增加相关。
- 6个月多西环素暴露后预防时,肠道微生物组的α多样性、β多样性和分类组成未观察到残留差异。
- 随着多西环素暴露后预防作为公共卫生策略实施,需要对多西环素耐药病原体进行进一步研究和人群水平监测以理解这些发现的含义。
研究设计与样本
- 研究为DoxyPEP随机临床试验(ClinicalTrials.gov注册号NCT03980223)的参与者样本分析。
- 比较多西环素暴露后预防组(DP组,n=100,无保护性行为后单次口服多西环素200 mg)与标准治疗组(SOC组,n=50),人群为男男性行为者和跨性别女性。
- 在入组时(第0天)和6个月后(第6个月)采集自采直肠拭子,进行宏基因组DNA测序或宏转录组RNA测序。
- DNA测序数据可分析样本127份来自89名参与者,RNA测序数据可分析样本86份来自70名参与者。
主要发现
- 有DNA测序数据的参与者中,SOC组自入组以来服用的多西环素剂量中位数为0剂(IQR:0-7剂),DP组为42剂(IQR:27-64剂)。
- 四环素耐药基因在第0天所有DNA测序样本中检出,在第0天85%的RNA测序样本中检出。
- DP组参与者四环素耐药基因在耐药组中的比例质量从第0天至第6个月在宏基因组中从46%升至51%(P=2.3×10⁻²),在宏转录组中从4%升至15%(P=4.5×10⁻⁶);其他耐药基因类别未观察到统计学显著增加。
- 较高的多西环素剂量暴露与宏基因组(Spearman ρ=0.23,P=9.0×10⁻³)和宏转录组(Spearman ρ=0.55,P=3.7×10⁻⁸)中四环素耐药基因的比例富集相关。
- 基于丰度的相关分析中,观察到四环素耐药基因与特定细菌分类群(包括一些常见人类病原体)之间的相关性强度随时间增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Doxycycline post-exposure prophylaxis (doxy-PEP) reduces bacterial sexually transmitted infections among men who have sex with men and transgender women. Although poised for widespread clinical implementation, the impact of doxy-PEP on antimicrobial resistance remains a primary concern as its effects on the gut microbiome and resistome, or the antimicrobial resistance genes (ARGs) present in the gut microbiome, are unknown. To investigate these effects, we studied participants from the DoxyPEP trial, a randomized clinical trial comparing doxy-PEP use, a one-time doxycycline 200-mg dose taken after condomless sex (DP arm, n = 100), to standard of care (SOC arm, n = 50) among men who have sex with men and transgender women. From self-collected rectal swabs at enrollment (day-0) and after 6 months (month-6), we performed metagenomic DNA sequencing (DNA-seq) or metatranscriptomic RNA sequencing (RNA-seq). DNA-seq data were analyzable from 127 samples derived from 89 participants, and RNA-seq data were analyzable from 86 samples derived from 70 participants. We compared the bacterial microbiome and resistome between the two study arms and over time. The median number of doxycycline doses taken since enrollment by participants with DNA-seq data was zero (interquartile range (IQR): 0-7 doses) for the SOC arm and 42 (IQR: 27-64 doses) for the DP arm. Tetracycline ARGs were detected in all day-0 DNA-seq samples and in 85% of day-0 RNA-seq samples. The proportional mass of tetracycline ARGs in the resistome increased between day-0 and month-6 in DP participants from 46% to 51% in the metagenome (P = 2.3 × 10-2) and from 4% to 15% in the metatranscriptome (P = 4.5 × 10-6), but no statistically significant increases in other ARG classes were observed. Exposure to a higher number of doxycycline doses correlated with proportional enrichment of tetracycline ARGs in the metagenome (Spearman's ρ = 0.23, P = 9.0 × 10-3) and metatranscriptome (Spearman's ρ = 0.55, P = 3.7 × 10-8). Bacterial microbiome alpha diversity, beta diversity and total bacterial mass did not differ between day-0 and month-6 samples from DP participants when assessed by either DNA-seq or RNA-seq. In an abundance-based correlation analysis, we observed an increase over time in the strength of the correlation between tetracycline ARGs and specific bacterial taxa, including some common human pathogens. In sum, doxy-PEP use over a 6-month period was associated with an increase in the proportion of tetracycline ARGs comprising the gut resistome and an increase in the expression of tetracycline ARGs. At 6 months of doxy-PEP use, no residual differences were observed in alpha and beta diversity or taxonomic composition of the gut microbiome. As doxy-PEP is implemented as a public health strategy, further studies and population-level surveillance of doxycycline-resistant pathogens are needed to understand the implications of these findings. ClinicalTrials.gov registration number: NCT03980223 .
引用
- Chu VT, Glascock A, Donnell D, et al. Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome. Nat Med. 2024. PMID: 39363100. doi:10.1038/s41591-024-03274-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。